Daiichi Sankyo

News

Manufacturing hangover drives Daiichi Sankyo into the red

Long-term third-party manufacturing contracts and a slower-than-expected rollout of its cancer ADCs have driven Daiichi Sankyo into a net loss.

News

Daiichi exits OTC, with $1.55bn unit sale to Suntory

Daiichi Sankyo has agreed to sell its consumer health unit to food and beverage giant Suntory, following a well-trodden path for big pharma companies.

News

Man on his smartphone while sitting on sifa

Daiichi teams up with GAIA for cholesterol DTx in Europe

Daiichi Sankyo has licensed European rights to GAIA's digital therapeutic for people with high cholesterol, currently in phase 3 testing.

Oncology

Daiichi Sankyo gears up for five ADC launches in 2026

On the sidelines of JPM, Daiichi-Sankyo US CEO Ken Keller told pharmaphorum about the company's big year and its long-term strategy in ADCs.

News

Ex-Novartis CMO John Tsai joins Daiichi Sankyo

Daiichi Sankyo has named John Tsai as its new global head of R&D, replacing Ken Takeshita, who is stepping down after five years in the role.

News

FDA knocks back AstraZeneca's self-injected lupus drug

FDA has delivered a setback to AstraZeneca by rebuffing its new formulation of lupus therapy Saphnelo, which was approved in Europe last year.

Manufacturing hangover drives Daiichi Sankyo into the red

Daiichi exits OTC, with $1.55bn unit sale to Suntory

Daiichi teams up with GAIA for cholesterol DTx in Europe

Daiichi Sankyo gears up for five ADC launches in 2026

Ex-Novartis CMO John Tsai joins Daiichi Sankyo

FDA knocks back AstraZeneca's self-injected lupus drug

Remepy's hybrid Parkinson's therapy poised for phase 3

Discover a new era of healthcare panel engagement: Grounded ...

Daiichi Sankyo

Editor's Picks